Richard A. Friedman
From Wikipedia, the free encyclopedia
Richard Alan Friedman is professor[ambiguous] of clinical psychiatry at Weill Cornell Medical College, attending psychiatrist at NewYork–Presbyterian Hospital[1] and director of psychopharmacology at the Payne Whitney Psychiatric Clinic.[2] He is an expert in the pharmacologic treatment of personality, mood and anxiety disorders, obsessive–compulsive disorder, PTSD and refractory depression.[3]
Friedman earned a B.A. in 1978 from Duke University and his M.D. in 1982 from Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey.[1]
In the 1980s, he was a psychiatrist at Payne Whitney Psychiatric Clinic and is a professor[ambiguous] at Weill Cornell Medical College.[4]
Research
Friedman has authored publications in the American Journal of Psychiatry, The New England Journal of Medicine and the Journal of the American Medical Association, among others.[3][4]
In 2014, Friedman's research activity was in the field of chronic depression, evaluating antidepressant medications, studying the effectiveness of long-term treatment; neurobiology and the social and occupational impairments.[4] He conducted a clinical study of medication for "double depression" (dysthymia with major depression), and evaluated the role of serotonin in chronic depression. He plans a study simultaneously examining brain activity with MRI, behavior, and serotonin functions in patients with chronic depression.[4]
Journalism
Since spring 2015, Friedman has been a contributing op-ed writer at The New York Times, writing about mental health, addiction, human behavior and neuroscience.[5] He has also been a longstanding contributor to the science section of The New York Times since 2002.[6] In 2011, he contributed to The New York Review of Books.[4]